This finding supports the potential application of tackling ROS in cancer immunotherapy.[53] Tumor mutational burden (TMB) and an expression signature of the antigen processing and presenting machinery have been used as effective tumor‐inherent biomarkers to predict cancer immunotherapy response.[54] In this study, we have demonstrated that more antigen‐specific CD8+ T cells were recruited to the TME upon GLS inhibition, those T cells were also more active and showed less exhaustion compared to the control group (Figure 3). The gene discussed is CD8A; the disease is cancer.